# The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

> **NCT03604406** · PHASE2 · COMPLETED · sponsor: **Kevin Winthrop** · enrollment: 154 (actual)

## Conditions studied

- Herpes Zoster
- Inflammatory Disease
- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Varicella Zoster Vaccine
- **OTHER:** Placebo Injection
- **BIOLOGICAL:** Varicella Zoster Vaccine

## Key facts

- **NCT ID:** NCT03604406
- **Lead sponsor:** Kevin Winthrop
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-08
- **Primary completion:** 2024-06-30
- **Final completion:** 2026-01-12
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03604406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03604406, "The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03604406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*